Search
AD 337
go.drugbank.com/drugs/DB05725InvestigationalAD 337 was under investigation in clinical trial NCT00377039 (A Multicentre Trial to Determine the Efficacy and Safety of AD-337 in the Treatment of Fibromyalgia).
IPH 1101
go.drugbank.com/drugs/DB05754ExperimentalIPH 1101 is a chemically-synthesized structural analog of non-conventional bacterial phosphoantigens which specifically activate the Vγ9Vδ2 T cell subset.
DNB-001
go.drugbank.com/drugs/DB05757InvestigationalDNB-001 is a first-in-class oral therapy with dual mechanism of action, which is initially being developed for the treatment of glaucoma.
Arylacenamide
go.drugbank.com/drugs/DB05792ExperimentalIt is a dual agent with both immunomodulatory and antiproliferative activities. … Arylacenamide (SR31747) is a peripheral [sigma] ligand that binds four proteins in human cells, i.e. SRBP-1, [sigma]-2, HSI and its relative SRBP-2.
Muparfostat
go.drugbank.com/drugs/DB05808InvestigationalMuparfostat (PI-88) is a mixture of highly sulfated, monophosphorylated mannose oligosaccharides, derived from the extracellular phosphomannan of the yeast Pichia (Hansenula) holstii, with potential antiangiogenic
GPI-1485
go.drugbank.com/drugs/DB05814InvestigationalGPI 1485 is a product candidate that belongs to a class of small molecule compounds called neuroimmunophilin ligands.
PPI-1019
go.drugbank.com/drugs/DB05832InvestigationalApan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.
Elsibucol
go.drugbank.com/drugs/DB05840ExperimentalAGI-1096 is a novel oral antioxidant and selective anti-inflammatory agent that is being developed to address the accelerated inflammation of grafted blood vessels, known as transplant arteritis, common
AI-850
go.drugbank.com/drugs/DB05842ExperimentalAI-850 is a Cremophor(R)-free formulation of paclitaxel, the active ingredient in Taxol(R), a product used to treat a variety of solid tumors.
BI-K0376
go.drugbank.com/drugs/DB05858ExperimentalBI-K0376 is a solid. It is under investigation by Pfizer and has gone through phase I of the clinical trails.